Monte Rosa Therapeutics Inc (GLUE)

Dec 20, 2024

Wells Fargo Downgrades Monte Rosa Therapeutics (GLUE) - MSN

Dec 20, 2024

Dec 19, 2024

Monte Rosa Therapeutics (NASDAQ:GLUE) Lowered to Equal Weight Rating by Wells Fargo & Company - MarketBeat

Dec 19, 2024

Dec 14, 2024

The Manufacturers Life Insurance Company Buys 15,168 Shares of Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) - Defense World

Dec 14, 2024

Dec 13, 2024

Monte Rosa Therapeutics Appoints Dr. Eric A. Hughes to Board of Directors - Marketscreener.com

Dec 13, 2024

Dec 13, 2024

Monte Rosa Therapeutics appoints new board member - Investing.com

Dec 13, 2024

Dec 13, 2024

Monte Rosa Therapeutics appoints new board member By Investing.com - Investing.com UK

Dec 13, 2024

Dec 13, 2024

Monte Rosa Therapeutics Strengthens Board with Teva's R&D Chief, Advancing Molecular Glue Platform - StockTitan

Dec 13, 2024

Dec 12, 2024

Monte Rosa reports promising cancer therapy results By Investing.com - Investing.com Nigeria

Dec 12, 2024

Dec 11, 2024

Monte Rosa reports promising cancer therapy results - Investing.com

Dec 11, 2024

Dec 11, 2024

Monte Rosa Therapeutics Announces Closing of Global License Agreement with Novartis to Advance T and B Cell-modulating VAV1-directed Molecular Glue Degraders - The Manila Times

Dec 11, 2024

Dec 11, 2024

Monte Rosa Therapeutics Presents Preclinical Data at the 2024 San Antonio Breast Cancer Symposium on the Potential of its CDK2-directed Molecular Glue Degraders to Treat HR-positive/HER2-negative Breast Cancer - The Manila Times

Dec 11, 2024

Dec 11, 2024

Monte Rosa Therapeutics Announces Closing of Global License - GlobeNewswire

Dec 11, 2024

Dec 11, 2024

Monte Rosa Therapeutics Presents Preclinical Data at the - GlobeNewswire

Dec 11, 2024

Dec 09, 2024

Intech Investment Management LLC Makes New $77,000 Investment in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) - Defense World

Dec 09, 2024

Dec 07, 2024

Monte Rosa Therapeutics (NASDAQ:GLUE) Shares Up 8.7%Here's What Happened - MarketBeat

Dec 07, 2024

Dec 06, 2024

Monte Rosa Therapeutics provides development progress on ongoing MRT-2359 study - Yahoo Finance

Dec 06, 2024

Dec 06, 2024

Monte Rosa Therapeutics (GLUE) Price Target Increased by 5.66% to 16.32 - MSN

Dec 06, 2024

Dec 05, 2024

Monte Rosa reports favorable MRT-2359 trial results By Investing.com - Investing.com Nigeria

Dec 05, 2024

Dec 05, 2024

Monte Rosa reports favorable MRT-2359 trial results - Investing.com India

Dec 05, 2024

Dec 05, 2024

Monte Rosa Therapeutics Provides Development Progress Update for Ongoing MRT-2359 Phase 1/2 Study in Patients with MYC-driven Solid Tumors - The Manila Times

Dec 05, 2024

Dec 05, 2024

Monte Rosa's Cancer Drug MRT-2359 Shows Promising Safety Profile in Phase 1/2 Trial - StockTitan

Dec 05, 2024

Dec 04, 2024

Monte Rosa Therapeutics: A First Assessment (NASDAQ:GLUE) - Seeking Alpha

Dec 04, 2024

Dec 04, 2024

Wall Street Analysts See a 64.09% Upside in Monte Rosa Therapeutics (GLUE): Can the Stock Really Move This High? - MSN

Dec 04, 2024

Nov 26, 2024

Monte Rosa Therapeutics to Participate in the Piper Sandler Healthcare Conference - The Manila Times

Nov 26, 2024

Nov 26, 2024

Monte Rosa Therapeutics CEO to Present at Piper Sandler Healthcare Conference | GLUE Stock News - StockTitan

Nov 26, 2024

Nov 20, 2024

Wall Street Analysts Think Monte Rosa Therapeutics (GLUE) Could Surge 100.47%: Read This Before Placing a Bet - MSN

Nov 20, 2024

Nov 16, 2024

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Sees Large Growth in Short Interest - MarketBeat

Nov 16, 2024

Nov 13, 2024

Monte Rosa Therapeutics to Participate in the Jefferies London Healthcare Conference - GlobeNewswire

Nov 13, 2024

Nov 13, 2024

Monte Rosa Therapeutics to Present at Jefferies Healthcare Conference: MGD Innovation Spotlight | GLUE Stock News - StockTitan

Nov 13, 2024

Nov 12, 2024

FMR LLC Increases Stake in Monte Rosa Therapeutics Inc - GuruFocus.com

Nov 12, 2024

Nov 12, 2024

News Flash: Analysts Just Made A Sizeable Upgrade To Their Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Forecasts - Simply Wall St

Nov 12, 2024

Nov 11, 2024

Owning 47% shares,institutional owners seem interested in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE), - Yahoo Finance

Nov 11, 2024

Nov 11, 2024

Wedbush Equities Analysts Raise Earnings Estimates for GLUE - MarketBeat

Nov 11, 2024

Nov 09, 2024

Monte Rosa Therapeutics (NASDAQ:GLUE) Earns “Outperform” Rating from Wedbush - Defense World

Nov 09, 2024

Nov 08, 2024

Monte Rosa Therapeutics Expands Pipeline with Novartis Deal - TipRanks

Nov 08, 2024

Nov 07, 2024

Monte Rosa Therapeutics earnings beat by $0.18, revenue topped estimates - Investing.com Canada

Nov 07, 2024

Nov 07, 2024

Monte Rosa Therapeutics: Q3 Earnings Snapshot - Barchart

Nov 07, 2024

Nov 07, 2024

Monte Rosa Therapeutics Inc (GLUE) Quarterly 10-Q Report - Quartzy

Nov 07, 2024

Nov 07, 2024

Wall Street Analysts Believe Monte Rosa Therapeutics (GLUE) Could Rally 67.24%: Here's is How to Trade - MSN

Nov 07, 2024

Nov 07, 2024

Are You Looking for a Top Momentum Pick? Why Monte Rosa Therapeutics (GLUE) is a Great Choice - MSN

Nov 07, 2024

Nov 07, 2024

Monte Rosa Therapeutics (GLUE) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance

Nov 07, 2024

Nov 07, 2024

Monte Rosa Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update - The Manila Times

Nov 07, 2024

Nov 07, 2024

Monte Rosa Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 07, 2024

Nov 07, 2024

Monte Rosa Secures $2.1B Novartis Deal, Extends Cash Runway to 2028 in Major Pipeline Win | GLUE Stock News - StockTitan

Nov 07, 2024

Oct 31, 2024

Equities Analysts Issue Forecasts for GLUE FY2024 Earnings - Defense World

Oct 31, 2024

Oct 31, 2024

Biogen, Neomorph pact worth $1.45B for molecular glue degraders - BioWorld Online

Oct 31, 2024